Kymera Therapeutics Outlines Key 2024 Objectives and Strategy to Progress Leading Portfolio of Immunology and Oncology Programs

January 9, 2024

https://www.globenewswire.com/news-release/2024/01/09/2806383/0/en/Kymera-Therapeutics-Outlines-Key-2024-Objectives-and-Strategy-to-Progress-Leading-Portfolio-of-Immunology-and-Oncology-Programs.html

IRAK4 oral degrader KT-474 (SAR444656) expected to complete enrollment in both Phase 2 HS and AD studies in fourth quarter of 2024, with topline data expected in first half of 2025

Read more at globenewswire.com

Related news for (KYMR)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.